[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,006,011
  • Shares Outstanding, K 70,959
  • Annual Sales, $ 105,970 K
  • Annual Income, $ -81,130 K
  • EBIT $ -156 M
  • EBITDA $ -144 M
  • 60-Month Beta 1.15
  • Price/Sales 19.43
  • Price/Cash Flow N/A
  • Price/Book 26.36

Options Overview Details

View History
  • Implied Volatility 66.87% (+11.49%)
  • Historical Volatility 47.30%
  • IV Percentile 13%
  • IV Rank 12.70%
  • IV High 220.79% on 11/14/25
  • IV Low 44.47% on 05/21/26
  • Expected Move (DTE 19) 0.68 (2.41%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 159
  • Volume Avg (30-Day) 594
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 7,624
  • Open Int (30-Day) 4,215
  • Expected Range 27.59 to 28.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.53
  • Number of Estimates 5
  • High Estimate $2.69
  • Low Estimate $2.14
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +1,073.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.52 +31.37%
on 08/03/26
30.62 -7.67%
on 08/26/26
+5.66 (+25.03%)
since 07/28/26
3-Month
21.52 +31.37%
on 08/03/26
30.62 -7.67%
on 08/26/26
+2.79 (+10.95%)
since 05/28/26
52-Week
13.60 +107.87%
on 09/03/25
30.62 -7.67%
on 08/26/26
+13.43 (+90.50%)
since 08/28/25

Most Recent Stories

More News
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line...

ZYME : 28.27 (-2.55%)
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

VANCOUVER, British Columbia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...

ZYME : 28.27 (-2.55%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...

ZYME : 28.27 (-2.55%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed...

ZYME : 28.27 (-2.55%)
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones...

ZYME : 28.27 (-2.55%)
Zymeworks Prepares to Defend a Ninety Percent Revenue Collapse Under Strengthened Cash Reserves

Barchart Research What to Expect from ZYME Earnings ZYME Generated August 5, 2026 Current Price $23.50 EPS Estimate $$-0.50 Consensus Rating Strong Buy Average Move 4.54% Zymeworks Prepares to Defend a...

ZYME : 28.27 (-2.55%)
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...

ZYME : 28.27 (-2.55%)
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed...

ZYME : 28.27 (-2.55%)
Zymeworks to Acquire Theravance Biopharma, Inc.

Acquisition adds YUPELRI ® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition...

ZYME : 28.27 (-2.55%)
Zymeworks to Acquire Theravance Biopharma, Inc.

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of...

TBPH : 17.05 (+0.06%)
ZYME : 28.27 (-2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 29.46
2nd Resistance Point 29.18
1st Resistance Point 28.73
Last Price 28.27
1st Support Level 28.00
2nd Support Level 27.72
3rd Support Level 27.27

See More

52-Week High 30.62
Last Price 28.27
Fibonacci 61.8% 24.12
Fibonacci 50% 22.11
Fibonacci 38.2% 20.10
52-Week Low 13.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.